Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 7-ethyl-4-(3-(4-ethylsulfonyl-2-methoxyphenyl)-4-fluorophenyl)imidazo(4,5-c)pyridazine
2. Pf-06372865
1. Pf-06372865
2. 1614245-70-3
3. Darigabat [inn]
4. Darigabat [usan]
5. Cvl-865
6. O9bp19hz3q
7. 7-ethyl-4-(4'-(ethylsulfonyl)-6-fluoro-2'-methoxybiphenyl-3-yl)-7h-imidazo[4,5-c]pyridazine
8. 7-ethyl-4-[3-(4-ethylsulfonyl-2-methoxyphenyl)-4-fluorophenyl]imidazo[4,5-c]pyridazine
9. 7h-imidazo(4,5-c)pyridazine, 7-ethyl-4-(4'-(ethylsulfonyl)-6-fluoro-2'-methoxy(1,1'-biphenyl)-3-yl)-
10. 7-ethyl-4-[4'-(ethylsulfonyl)-6-fluoro-2'-methoxybiphenyl-3-yl]-7h-imidazo[4,5-c]pyridazine
11. Unii-o9bp19hz3q
12. Gtpl9798
13. Chembl3647536
14. Schembl15794150
15. Bdbm144227
16. Tq0078
17. Who 11498
18. Example 4 [wo2014091368]
19. Bp166580
20. Hy-120874
21. Cs-0079452
22. Pf06372865
23. Pf 06372865
24. Us8952008, 4
25. 7-ethyl-4-(4'-(ethylsulfonyl)-6-fluoro-2'-methoxy-[1,1'-biphenyl]-3-yl)-7h-imidazo[4,5-c]pyridazine
26. 7-ethyl-4-(4'-(ethylsulfonyl)-6-fluoro-2'-methoxybiphenyl-3-yl)-7h-imidazo(4,5-c)-pyridazine
27. 7-ethyl-4-(4'-(ethylsulfonyl)-6-fluoro-2'methoxybiphenyl-3-yl)-7h-imidazo[4,5-c]pyridazine
| Molecular Weight | 440.5 g/mol |
|---|---|
| Molecular Formula | C22H21FN4O3S |
| XLogP3 | 2.9 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 6 |
| Exact Mass | 440.13183988 g/mol |
| Monoisotopic Mass | 440.13183988 g/mol |
| Topological Polar Surface Area | 95.4 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 705 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
GABA Modulators
Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
77
PharmaCompass offers a list of Darigabat API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Darigabat manufacturer or Darigabat supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Darigabat manufacturer or Darigabat supplier.
PharmaCompass also assists you with knowing the Darigabat API Price utilized in the formulation of products. Darigabat API Price is not always fixed or binding as the Darigabat Price is obtained through a variety of data sources. The Darigabat Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Darigabat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Darigabat, including repackagers and relabelers. The FDA regulates Darigabat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Darigabat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Darigabat supplier is an individual or a company that provides Darigabat active pharmaceutical ingredient (API) or Darigabat finished formulations upon request. The Darigabat suppliers may include Darigabat API manufacturers, exporters, distributors and traders.
Darigabat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Darigabat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Darigabat GMP manufacturer or Darigabat GMP API supplier for your needs.
A Darigabat CoA (Certificate of Analysis) is a formal document that attests to Darigabat's compliance with Darigabat specifications and serves as a tool for batch-level quality control.
Darigabat CoA mostly includes findings from lab analyses of a specific batch. For each Darigabat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Darigabat may be tested according to a variety of international standards, such as European Pharmacopoeia (Darigabat EP), Darigabat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Darigabat USP).
